While the roles of glutamic acid （Glu）, arginine vasopressin （AVP） and their respective receptors in anxiety have been thoroughly investigated, the effects of interactions among Gila, N-methyl-D-aspartic acid （NMDA） receptor, AVP and a-amino-3- hydroxy-5-methylisoxazole-4-propionic acid （AMPA） receptor on anxiety are still unclear. In the present study, the agonist and antagonist of the NMDA receptor and AMPA receptor, as well as the antagonist of AVP V1 receptor （VlaR） were introduced into BALB/cJ mice by intracerebroventricular microinjection, and the anxiety-like behaviors of the mice were evaluated by open field and elevated plus-maze tests. Compared with C57BL/6 mice, BALB/cJ mice displayed higher levels of anxiety-like behavior. Significant anxiolytic effects were found in the NMDA receptor antagonist （MK-801） and the AMPA receptor or VlaR antagonist （SSRI49415）, as well as combinations of AVP/MK-801 and SSRI49415/DNQX. These results indicated that anxiety-like behaviors expressed in BALB/CJ mice may be due to a coordination disorder among glutamate, NMDA receptor, AMPA receptor, AVP and V1 aR, resulting in the up-regulation of the NMDA receptor and VlaR and down-regulation of the AMPA receptor. However, because the AMPA receptor can execute its anxiolytic function by suppressing AVP and VlaR, we cannot exclude the possibility of the NMDA receptor being activated by AVP acting on V1 aR.
